Evidence map›Paper›PMID 32728120›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2021

Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model.

Masaki Yamazaki, Atsuhiko Kato, Eiji Oki, Yoko Zaitsu, Chie Kato, Kiyotaka Nakano, Miho Nakamura, Takuya Sakomura, Shigeto Kawai, Etsuko Fujii and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Masaki YamazakiResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan. yamazakimsk@chugai-pharm.co.jp.ORCID 0000-0002-2079-0084
Atsuhiko KatoResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yoko ZaitsuDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Chie KatoResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Kiyotaka NakanoForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo, 153-8904, Japan.
Miho NakamuraForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo, 153-8904, Japan.
Takuya SakomuraForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo, 153-8904, Japan.
Shigeto KawaiForerunner Pharma Research Co., Ltd., Komaba Open Laboratory, The University of Tokyo, 4-6-1, Komaba, Meguro-ku, Tokyo, 153-8904, Japan.ORCID 0000-0002-3746-0794
Etsuko FujiiResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Noriaki SawadaResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Takeshi WatanabeChugai Research Institute for Medical Science, Inc., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Hiroshi SaekiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Masami SuzukiResearch Division, Chugai Pharmaceutical Co. Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Chugai Pharma (United States) · USTokyo Metropolitan Komaba High School · JPKyushu University · JPBoZo Research Center (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New cancer characteristics can be discovered by focusing on the process of tumor formation. Cancer stem cells (CSCs) are a key subpopulation, as they are theorized to be at the apex of the tumor hierarchy. We can better understand their function in the tumor hierarchy by using sectioned samples to observe the growth of tumors from their origins as CSCs. In this study, we evaluated the growth of moderate differentiated colorectal cancer from LGR5-positive cells, which is a CSC marker of colorectal cancer, using xenograft and three-dimensional culture models spatiotemporally. These cells express LGR5 at high levels and show CSC phenotypes. To detect them, we used a previously generated antibody that specifically targets LGR5, and were therefore able to observe LGR5-positive cells aggregating into small clusters (sCLs) over the course of tumor growth. Because these LGR5-expressing sCLs formed continuously during growth mainly in the invasive front, we concluded that the structure must contribute significantly to the expansion of CSCs and to tumor growth overall. We confirmed the formation of sCLs from gland structures using a three-dimensional culture model. In addition, sCLs exhibited upregulated genes related to stress response and partial/hybrid epithelial-mesenchymal transition (EMT), as well as genes reported to be prognosis factors. Finally, sCLs with high LGR5 expression were identified in clinical samples. Based on these results, we elucidate how sCLs are an important contributors to tumor growth and the expansion of CSCs.

Indexed as

AdenocarcinomaAnimalsCell Line, TumorCoculture TechniquesColonColorectal NeoplasmsEpithelial-Mesenchymal TransitionFibroblastsHumansMiceNeoplasms, ExperimentalNeoplasm TransplantationNeoplastic Stem CellsReceptors, G-Protein-CoupledLGR5 protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID32728120
OpenAlexW3045627779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.